A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease (MRD) status on first line nilotinib treatment.
The purpose of this study is to learn if the study drug, nilotinib, can be safely stopped being taken with no return of CML in patients who responded well on the treatment in the past.
chronic myeloid leukemia (CML)
Patients with chronic myeloid leukemia (CML) who started treatment with nilotinib when they were first diagnosed with CML and continued this treatment for at least 24 months and have only a very small amount of leukemia cells remaining are eligible for the study.
18 - 100
Healthy Volunteers Needed
Duration of Participation
244 weeks (about 5 years)
Knight Cancer Intake Center: (503) 494-7999
Clinical Trials Information Line: (503) 494-1080 or firstname.lastname@example.org
Novartis Pharmaceuticals, Inc.